Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants

被引:1
|
作者
Enlund-Cerullo, Maria [1 ,2 ,3 ,4 ]
Holmlund-Suila, Elisa [1 ,2 ,4 ]
Valkama, Saara [1 ,2 ,4 ]
Hauta-alus, Helena [1 ,2 ,4 ,5 ,6 ,7 ]
Rosendahl, Jenni [1 ,2 ,4 ]
Andersson, Sture [1 ,2 ]
Pekkinen, Minna [1 ,2 ,3 ,4 ]
Makitie, Outi [1 ,2 ,3 ,4 ,8 ,9 ]
机构
[1] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[2] Helsinki Univ Hosp, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[3] Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland
[4] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland
[5] Natl Inst Hlth & Welf THL, Publ Hlth Res, Helsinki, Finland
[6] Oulu Univ Hosp, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[7] Univ Oulu, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[8] Karolinska Univ Hosp, Dept Mol Med & Surg, Stockholm, Sweden
[9] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Clin Genet, Stockholm, Sweden
基金
瑞典研究理事会; 芬兰科学院;
关键词
FGF23; genetic variation; vitamin D; bone strength; infants (0-24 months); DOMINANT HYPOPHOSPHATEMIC RICKETS; PHYSIOLOGICAL-ROLE; MINERAL DENSITY; VITAMIN-D; PHOSPHATE; MUTATIONS; CHILDREN;
D O I
10.3389/fgene.2023.1192368
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: The effects of genetic variation in fibroblast growth factor 23 (FGF23) are unclear. This study explores the associations of single-nucleotide polymorphisms (SNPs) of FGF23 with phosphate and vitamin D metabolism and bone strength in early childhood. Methods: The study is part of the vitamin D intervention in infant (VIDI) trial (2013-2016), in which healthy term infants born to mothers of Northern European origin received vitamin D-3 supplementation of 10 or 30 mu g/day from 2 weeks to 24 months of age (ClinicalTrials.gov NCT01723852). Intact and C-terminal FGF23 (cFGF23), 25-hydroxyvitamin D (25-OHD), parathyroid hormone, phosphate, and peripheral quantitative computed tomography (pQCT)-derived bone strength parameters were analyzed at 12 and 24 months. The study included 622 VIDI participants with genotyping data on FGF23 SNPs rs7955866, rs11063112, and rs13312770. Results: Rs7955866 minor allele homozygotes had lowest cFGF23 at both time-points (mixed model for repeated measurements, p(variant) = 0.009). Minor alleles of rs11063112 were associated with a greater age-related decrease in phosphate concentration (p(interaction) = 0.038) from 12 to 24 months. Heterozygotes of rs13312770 had the greatest total bone mineral content (total BMC), cross-sectional area (total CSA), and polar moment of inertia (PMI) at 24 months (ANOVA p = 0.005, 0.037, and 0.036, respectively). Rs13312770 minor alleles were associated with a greater increase of total BMC, but a smaller increase of total CSA and PMI, during follow-up (p(interaction) <0.001, 0.043, and 0.012, respectively). Genotype of FGF23 did not modify 25-OHD. Conclusion: The study finds that genetic variation in FGF23 modifies cFGF23, phosphate, and pQCT-derived bone strength parameters from 12 to 24 months of age. These findings potentially promote an understanding of the regulation of FGF23 and its role in bone metabolism and temporal changes thereof during early childhood.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] FGF23 associated bone diseases
    Eryuan Liao
    Frontiers of Medicine, 2013, 7 : 65 - 80
  • [42] FGF23 associated bone diseases
    Liao, Eryuan
    FRONTIERS OF MEDICINE, 2013, 7 (01) : 65 - 80
  • [43] SERUM FIBROBLAST GROWTH FACTOR TYPE 23 (FGF23) IN THE EARLY AND POSTTRANSPLANTATION PERIOD IN KIDNEY ALLOGRAFT RECIPIENTS
    Nimgirova, Aysa
    Esayan, Ashot
    Kayukov, Ivan
    Zuyeva, Ekaterina
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 513 - 513
  • [44] NOVEL ELISA ALLOWS ACCURATE QUANTIFICATION OF INTACT FIBROBLAST GROWTH FACTOR 23 (FGF23) IN SERUM AND PLASMA
    Wallwitz, J.
    Gadermaier, E.
    Berg, G.
    Himmler, G.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S531 - S532
  • [45] Ablation of the Galnt3 Gene Leads to Low-Circulating Intact Fibroblast Growth Factor 23 (Fgf23) Concentrations and Hyperphosphatemia Despite Increased Fgf23 Expression
    Ichikawa, Shoji
    Sorenson, Andrea H.
    Austin, Anthony M.
    Mackenzie, Donald S.
    Fritz, Timothy A.
    Moh, Akira
    Hui, Siu L.
    Econs, Michael J.
    ENDOCRINOLOGY, 2009, 150 (06) : 2543 - 2550
  • [46] New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis
    Mace, Maria L.
    Olgaard, Klaus
    Lewin, Ewa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 20
  • [47] Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans
    Sharma, Shilpa
    Katz, Ronit
    Ginsberg, Charles
    Bullen, Alexander
    Vallon, Volker
    Thomson, Scott
    Moe, Orson W.
    Hoofnagle, Andrew N.
    de Leeuw, Peter W.
    Kroon, Abraham A.
    Houben, Alfons J. H. M.
    Ix, Joachim H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (06) : 1170 - 1178
  • [48] Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study
    Brandenburg, Vincent M.
    Kleber, Marcus E.
    Vervloet, Marc G.
    Tomaschitz, Andreas
    Pilz, Stefan
    Stojakovic, Tatjana
    Delgado, Graciela
    Grammer, Tanja B.
    Marx, Nikolaus
    Maerz, Winfried
    Scharnagl, Hubert
    ATHEROSCLEROSIS, 2014, 237 (01) : 53 - 59
  • [49] Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis
    Nishizawa, Yoko
    Hosoda, Yumi
    Horimoto, Ai
    Omae, Kiyotsugu
    Ito, Kyoko
    Higuchi, Chieko
    Sakura, Hiroshi
    Nitta, Kosaku
    Ogawa, Tetsuya
    HEART AND VESSELS, 2021, 36 (03) : 414 - 423
  • [50] FIBROBLAST GROWTH FACTOR 23 (FGF23) AND DIASTOLIC DYSFUNCTION IN PAEDIATRIC CHRONIC KIDNEY DISEASE
    Koh, Chee Teck
    Lu, Liangjian David
    Teo, Sher Leen Sharon
    Than, Mya
    Lau, Yew Weng Perry
    Quek, Swee Chye
    Ling, Lieng Hsi
    Gong, Lingli
    Chen, Ching Kit
    Ng, Kar Hui
    Liu, Desheng Isaac
    Yap, Hui Kim
    PEDIATRIC NEPHROLOGY, 2021, 36 (09) : 2944 - 2944